Ask Warren

JONBUR Research · Initiation

OSCOTECInc · 039200 · Biotech & Pharma

OSCOTEC: Profits Turn Sharply Positive Since 2024 While Shares Trade Well Below 52-Week High

Why this report

Start of coverage: one of the 300 largest companies, written once its financial statements were in.

Filed financials show OSCOTEC moving from years of operating losses to trailing revenue of ₩144.2B and operating income of ₩89.7B as of H1 2026. The share price closed at ₩36,500 on 2026-10-12, up 23.7% over three months but down 19.4% over one year.

Written Oct 13, 2026 · Data as of Oct 12, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a sharp change in earnings. Revenue rose from ₩5.0B in 2023 to ₩99.8B in 2025, and the trailing twelve months to H1 2026 reached ₩144.2B. Operating margin moved from -659.6% in 2023 to 62.2% on a trailing basis.

What the data does not show is why revenue changed or whether it will repeat. The figures are lumpy, with revenue growth of 586.9% in 2024 and 193.6% in 2025, after flat years. Revenue sources, contract terms and guidance are not in the data, so durability of the profits cannot be judged here.

The share price is ₩36,500 versus a 52-week range of ₩27,300 to ₩66,000, so it sits about 44.7% below the high. Investor flows, foreign ownership and short balance data are not available.

Business overview

OSCOTEC is a KOSDAQ-listed company in the Biotech & Pharma sector. It was founded on 1998-12-08 and listed on 2007-01-17, with 38,248,176 listed shares. Market capitalization is about ₩1.4T and enterprise value is about ₩1.37T. Co-CEOs are listed as 윤태영 and 이상현.

The history of the numbers shows small revenue from 2021 to 2023 (₩3.9B, ₩5.1B, ₩4.9B) with operating losses of roughly ₩28B to ₩33B a year. Revenue jumped to ₩34.0B in 2024 and ₩99.8B in 2025.

Financial analysis

These figures come from filed financial statements (DART). In 2025, revenue was ₩99.8B, operating income ₩52.1B (52.2% margin) and net income ₩52.3B, with ROE of 33.9%. In 2024, operating income was -₩2.7B and net income was ₩0.9B.

Trailing twelve months to H1 2026: revenue ₩144.2B, operating income ₩89.7B, net income ₩94.1B, operating margin 62.2%, net margin 65.2% and ROE 54.7%. Net income exceeds operating income, so non-operating items contributed, though details are not in the data.

The balance sheet looks light on debt: liabilities to equity of 19.2%, borrowings of ₩6.0B and cash of ₩32.4B. Free cash flow was ₩90.6B on a trailing basis.

Valuation

Current multiples are P/E 14.8, P/B 6.5, P/S 9.7 and EV/EBITDA 15.0. No dividend yield is available. At year-end 2025 P/E was 33 and P/B was 9.5, so both multiples are lower now, largely because trailing earnings have grown.

Peers in the data: Samsung Biologics (P/E 43.1, P/B 10.2), Celltrion (24.5, 2.2), Alteogen (63.9, 23.0), Hanmi Pharm (28.0, 4.3) and HLB (P/E not available, P/B 16.9). OSCOTEC's P/E is below all peers with a P/E, while its P/B is mid-range. Peers differ in size and business, so the comparison is rough.

The valuation model estimate is not available (fair_value_model is null), so no model estimate per share can be compared with the price of ₩36,500.

Catalysts

  • A shareholders' meeting was called on 2026-10-06, alongside a record date or register closure notice.
  • A lawsuit filing or ruling was disclosed on 2026-09-23, and its details are not in the data.
  • A 'major management matter relevant to investors' filing appeared on 2026-09-04, with content not given.
  • Multiple 5%+ holding reports (Aug-Sep 2026) and an amended change of largest shareholder filing (2026-07-23) point to shifting ownership.
  • The H1 2026 half-year report was filed on 2026-08-14, followed by an IR event on 2026-08-20.

Risks

  • Earnings history is short: the company posted operating losses through 2024, so the profitable record covers only about two years.
  • Trailing net income and operating income are large relative to prior years, and their source and repeatability are not shown in the data.
  • The share price fell 19.4% over one year and sits far below its 52-week high, showing high volatility.
  • The lawsuit filing and ownership-related filings carry unknown outcomes, since the data gives only titles.
  • Investor flow, foreign ownership, short interest and news data are unavailable, limiting insight into market positioning.

Closing view

The filed data shows a clear break from loss-making years to high margins and strong cash flow, with low debt. On trailing earnings, the P/E of 14.8 is below its year-end 2025 level and below peers that report one, though peers are not directly comparable. Missing information on revenue drivers, the lawsuit, ownership changes, flows and a model estimate means the durability of these results remains an open question rather than something the data settles.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 13, 2026InitiationStart of coverage (300 largest)OSCOTEC: Profits Turn Sharply Positive Since 2024 While Shares Trade Well Below 52-Week High

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information